AVR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Anteris Technologies (AVR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent financing has reduced capital risk, and its partnership with Medtronic adds credibility and potential for future growth. Despite short-term financial challenges, the company's focus on a differentiated product in the medical device market and ongoing pivotal trials position it well for long-term success.
The technical indicators show a bullish trend. The MACD is positive and expanding, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near resistance levels (R1: 6.329). RSI is neutral at 78.044, suggesting no immediate overbought or oversold conditions.
The company has secured $320M in financing, including a strategic investment from Medtronic, which validates its product's viability and reduces financial risk. FDA approval for the PARADIGM Trial and ongoing pivotal trials are strong growth drivers.
indicates potential price swings.
In Q3 2025, revenue dropped by 44.21% YoY to $429,000. However, net income improved slightly (-1.76% YoY), and gross margin increased significantly to 71.33% (up 68.55% YoY). EPS also improved to -0.62, up 1.64% YoY.
Analysts have a positive outlook, with Barclays maintaining an Overweight rating and Lake Street keeping a Buy rating. Both firms lowered price targets due to the dilutive impact of recent financing but highlighted the strategic importance of the Medtronic partnership and reduced capital risk.
